Recent developments in meta-benziporphodimethene: A new porphyrin analogue

Structural characterization and bioimaging of Zn2+ using meta-benziporphodimethene analogue

"Prevention is better than cure, especially when something has no cure." Cancer, in most patients is detected at the stage beyond which it becomes non-curative. Thus, the early detection of cancer cells can play a crucial role in enhancing the chances of a patient's survival. In this light, we present a non-fluorescent receptor employed for the detection of Zn²⁺ ion in MDA-MB-231 carcinoma cells that exhibits fluorescence turn-on behaviour upon binding with the metal ion. In this work, the synthesis of 11,16-bis(2,6-difluorobenzene)-6,6,21,21-tetramethyl-meta-benziporpho-6,21-dimethene and its Zn²⁺ chloride complex have been reported. The compounds were fully characterized using UV-Visible, NMR, IR and mass spectrometry. Furthermore, the X-ray polymorphs of meta-benziporphodimethene analogue have been added. The study of its bioimaging applications in MDA-MB-231 breast cancer cells for the detection of Zn²⁺ ions have been reported.